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ABSTRACT
Objectives To estimate the cost savings and health 
beneits of improving detection of individuals at high risk 
of cardiovascular disease (CVD) in England, to determine 
to which patient subgroups these beneits arise, and to 
compare different strategies for subsequent management.
Design An economic analysis using the School for Public 
Health Research CVD Prevention Model.
Setting England 2018.
Participants Adults aged 16 and older with one or more 
high cardiovascular risk conditions, including hypertension, 
diabetes, non- diabetic hyperglycaemia, atrial ibrillation, 
chronic kidney disease and high cholesterol.
Interventions Detection of 100% of individuals with 
CVD high risk conditions compared with current levels of 
detection in England. Detected individuals are assumed 
to be managed either according to current levels of care 
or National Institute of Health and Care Excellence (NICE) 
guidelines.
Main outcome measures Incremental and cumulative 
costs, savings, quality adjusted life years (QALYs), CVD 
cases, and net monetary beneit, from a UK NHS and 
Personal Social Services perspective.
Results £68 billion could be saved, 4.9 million QALYs 
gained and 3.4 million cases of CVD prevented over 25 
years if all individuals in England with the six CVD high risk 
conditions were diagnosed and subsequently managed at 
current levels. Additionally, if all detected individuals were 
managed according to NICE guidelines, total savings would 
be £61 billion, 8.1 million QALYs would be gained and 
5.2 million CVD cases prevented. Most beneits come from 
detection of high cholesterol in the short term and diabetes 
in the long term.
Conclusions Substantial cost savings and health 
beneits would accrue if all individuals with conditions 
that increase CVD risk could be diagnosed, with detection 
of undiagnosed diabetes producing greatest beneits. 
Ensuring all conditions are managed according to 
NICE guidelines would further increase health beneits. 
Projected cost- savings could be invested in developing 
acceptable and cost- effective solutions for improving 
detection and management.
INTRODUCTION
Cardiovascular disease (CVD) prevention is 
a major global public health priority, despite 
recent reductions in mortality.1 2 Currently 
there are over 1.8 million people in England 
on the Coronary Heart Disease Register and 
over 1 million on the Stroke or Transient 
Ischaemic Attacks Register,2 with CVD esti-
mated to cost the UK economy €26 billion 
overall in 2015.1 As part of its strategy to 
improve CVD prevention, NHS RightCare 
Strengths and limitations of this study
 Ź Based on a single modelling framework that in-
cludes most elements of current cardiovascular dis-
ease (CVD) prevention practice in people at high risk 
in England, and thereby enables valid comparison of 
different detection and management scenarios.
 Ź The patient- level model structure preserves correla-
tions between high risk conditions, meaning that the 
combined beneits of detecting multiple high risk 
conditions can be assessed without either double 
counting or underestimating CVD risk in people with 
multiple comorbidities.
 Ź Results depend on accurate modelling of current 
care in England; however, this depends on a range 
of data sources that vary between highly accurate 
Quality and Outcomes Framework data and pub-
lished observational studies based on a limited 
sample.
 Ź The CVD prevention beneits of improving detection 
and management could be underestimated because 
the model does not include some vascular condi-
tions such as peripheral vascular disease, does not 
include CVD beneits of lifestyle management inter-
ventions that go beyond the recorded effect on met-
abolic factors, and does not model secondary CVD 
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has highlighted six high risk conditions for CVD that 
are currently under- diagnosed and insufficiently well 
managed despite a range of available interventions.3 
These conditions include hypertension, atrial fibrilla-
tion (AF), high cholesterol/high CVD risk comprising 
those with a QRISK score of at least 10% and those with 
familial hypercholesterolaemia (FH), diabetes (type 
1 and type 2), non- diabetic hyperglycaemia (NDH; 
HbA1c 42–48 mmol/mol), and chronic kidney disease 
(CKD). Many CVD events are preventable through 
pharmacological interventions and lifestyle changes. 
Clinical guidelines in Europe and several other coun-
tries support population wide programmes to assess 
and manage cardiovascular risk in individuals.4 Exam-
ples of national CVD risk assessment and management 
programmes include the NHS Health Check programme 
in England,5 Keep Well in Scotland6 and More Heart 
and Diabetes Checks in New Zealand.7 Nevertheless, in 
England detection rates for cardiovascular risk remain 
low and significant opportunities remain to reduce risks 
through treatment and lifestyle changes.8 9
While it appears evident that increasing diagnosis 
and management of these six conditions could be an 
achievable way of making health improvements and 
potentially saving costs to the NHS, little quantification 
of the potential benefits has been carried out. While 
evaluations of the NHS Health Checks have considered 
the benefits of increased uptake of statins, antihyper-
tensive treatment and lifestyle modification, detection 
and management of diabetes, NDH, CKD, and AF were 
not within the scope of these previous analyses.10–12 In 
2017, Public Health England (PHE) produced the Size 
of the Prize in CVD prevention,13 an analysis which esti-
mates the potential benefits of increasing treatment for 
hypertension and AF, but does not consider the impact 
of improving detection, nor include the other high risk 
conditions. Modelling of the entire diagnostic and treat-
ment pathway has been carried out for some conditions 
including AF,14 while other evaluations have considered 
particular CVD prevention strategies (eg, statins15). 
However, no previous analysis has considered all six high 
risk conditions and their currently used interventions 
within a single framework that enables valid compar-
ison between different detection and management 
guidelines.
The aim of this analysis was to estimate the total cost 
savings and health benefits that could be produced if it 
were possible to detect all individuals with the six high 
risk conditions in England, assuming that diagnosed indi-
viduals would be either managed to current care levels, 
or optimally according to National Institute for Health 
and Care Excellence (NICE) guidelines. In addition, 
the analysis explored which high risk groups benefit the 
most from optimal detection in terms of cost savings and 




The analysis was carried out using the School for Public 
Health Research (SPHR) CVD Prevention Model, devel-
oped as an adaptation of the SPHR Diabetes Preven-
tion Model, which has been previously used to evaluate 
a range of diabetes prevention strategies, including the 
NHS Diabetes Prevention Programme (NHS DPP).16–18 
Online supplementary file 1 includes full details of the 
model background and adaptations. In brief, the model 
is an individual patient microsimulation model written 
in R, with annual cycles and a lifetime horizon, based 
on correlated personalised trajectories of metabolic risk 
factors (body mass index, blood pressure, cholesterol and 
HbA1c). The model setting is the English NHS and social 
services. Baseline patient characteristics are taken from 
the Health Survey for England (HSE) 201419 to enable 
a patient population representative of England to be 
modelled.
Model development and assumptions
In any year of the model, individuals may develop one 
or more of the included six high risk conditions (hyper-
tension, high cholesterol (defined as QRISK2 score for 
CVD risk ≥10% or FH), type 1 and 2 diabetes, NDH, AF 
and CKD), and undergo diagnosis and management with 
one or more CVD prevention interventions, according 
to eligibility criteria. Interventions for inclusion in the 
model were selected from the NICE guidance for each 
of the high risk conditions.20–27 These include diagnostic 
interventions (NHS Health Check, annual review for 
people with a pre- existing high risk condition, cascade 
testing for FH and opportunistic diagnosis), pharmaco-
logical interventions (lipid modification, antihyperten-
sives, anticoagulants and diabetes treatments), lifestyle 
interventions (weight management, smoking cessation, 
structured education for diabetes, NHS DPP and nutri-
tional advice for CKD) and interventions to improve 
adherence to other interventions (blood pressure self- 
monitoring, medicines use review and insulin pump for 
type one diabetes). A series of rapid reviews were carried 
out to identify the best quality evidence around effective-
ness and costs for each intervention. A small number of 
NICE recommended interventions were not included 
due to insufficient data quality (alcohol brief interven-
tions, exercise referral and brief diet and lifestyle advice). 
Full details of the search strategies, reviewing method-
ology and results can be found in online supplementary 
file 1. Decisions about which evidence and assumptions 
to include in the model (eg, around duration of effect 
for each intervention, or eligibility criteria) were taken in 
conjunction with clinical experts.
Primary CVD events are modelled using a combination 
of QRISK2 and QStroke algorithms to assign separate 
annual cardiac and stroke risks,28 29 with event rates deter-
mined stochastically. QRISK2 includes myocardial infarc-
tion (MI), angina, stroke and transient ischaemic attack 
(TIA). Congestive heart failure is modelled separately 
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using Framingham risk equations.30 Other CVD condi-
tions (eg, peripheral vascular disease) are not modelled. 
Modifications were made to the QRISK and QStroke algo-
rithms to enable the CVD impact of all high risk condi-
tions and interventions to be included. QRISK2 and 
QStroke are only valid for estimating risk of primary CVD 
events; subsequent CVD events were modelled based on 
individual age, sex and prior CVD event only. Calibration 
was carried out to ensure that the total annual event rate 
for MI and stroke matched current data from Hospital 
Episode Statistics.31 In addition to CVD, individuals in the 
model also have an annual risk of developing microvas-
cular complications of diabetes, major bleeding, osteo-
arthritis, depression, breast and bowel cancer, dementia, 
and of dying. Each health state is associated with health-
care costs (with stroke, osteoarthritis and dementia also 
associated with social care costs), and a health- related 
quality of life decrement (online supplementary file 1). 
Model outcomes include costs in 2017/18 UK pounds, 
life years, quality adjusted life years (QALYs), cost- 
effectiveness (measured through net monetary benefit 
(NMB), assuming a value of £20 000 per QALY) and 
CVD events prevented. Costs, QALYs and life years were 
discounted at 3.5% according to the NICE reference case.
The model includes correlation between different 
chronic diseases in several different ways (described 
fully in online supplementary file 1). First, many of the 
modelled conditions are represented in HSE 2014 so there 
is correlation between conditions from baseline. Second, 
the trajectories of metabolic risk factors (BMI, blood pres-
sure, cholesterol and HbA1c) are correlated with each 
other and with other patient characteristics. Third, many 
of the risk equations used in the model to determine risk 
of disease for one condition have coefficients relating 
to one or more of the other conditions. Fourth, diag-
nostic criteria for each condition and the probability that 
individuals undergo diagnostic tests vary depending on 
whether or not another underlying condition is present. 
No good evidence about differential treatment effects in 
people with additional comorbid conditions or under-
going multiple treatment interventions could be identi-
fied, so potential correlations between treatments were 
not included; this is a limitation of the model.
Model analyses
To compare current care levels of detection and manage-
ment in England with improved levels of detection and 
management it was essential to obtain good quality 
information about the proportions of people currently 
diagnosed with each high risk condition and well 
managed using each intervention included in the model 
(summarised in table 1). Estimates of the total numbers 
of people currently suffering from each high risk condi-
tion were obtained from National Cardiovascular Intel-
ligence Network (NCVIN) prevalence models (available 
for AF, diabetes, hypertension and CKD),32–35 and data 
within the HSE 2014,19 while diagnosed prevalence was 
obtained primarily from the Quality and Outcomes 
Framework (QOF) 2016/17.36 The percentage currently 
diagnosed with each high risk condition was calculated by 
dividing the diagnosed prevalence by the total estimated 
prevalence. Current care management was estimated 
separately for each modelled intervention that a high 
risk group was eligible for (see table 1 and online supple-
mentary file 1), and was defined as the number currently 
undergoing each intervention divided by the number 
eligible for that intervention. A variety of data sources were 
used, including QOF,36 the National Diabetes Audit,37 the 
NHS DPP pilot study,38 NHS Digital: NHS Stop smoking 
services,39 and published data found through searches 
(see online supplementary file 1 for details).
Two analyses were carried out. In the first analysis, 
current care levels of detection and management with 
each intervention were compared against a scenario of 
100% diagnosis of all high risk conditions, assuming 
either current levels of management or management of 
all diagnosed, eligible individuals with each intervention 
according to NICE guidelines, to obtain an estimate of the 
total benefits that could be accrued through maximising 
detection. This was achieved by assuming that all individ-
uals with a high risk condition at baseline were diagnosed 
in the first modelled year, and that anyone developing a 
high risk condition in subsequent years would be diag-
nosed within the year of developing the condition. It 
was assumed that current levels of NHS Health Check 
and annual review were operating and that all additional 
diagnoses occurred through unspecified opportunistic 
detection mechanisms, for which the cost of diagnosis in 
individuals with high risk conditions was included, but 
the (unknown) cost of detecting the additional cases was 
not. Under the scenario of 100% detection and NICE 
guideline management, it was additionally assumed that 
all individuals would undergo all interventions for which 
they were eligible according to NICE guidelines, with 
100% uptake and 0% discontinuation.
In the second analysis, each high risk group was analysed 
separately to investigate the proportional share of bene-
fits obtained by each group through optimising detection 
and management. To achieve this objective, the detec-
tion of each high risk condition in turn was set to 100%, 
again assuming either current levels of management with 
each intervention or NICE guideline management of the 
high risk condition. Detection strategies were compared 
in terms of total benefits to the NHS, assessed at 5, 10 
and 25 year time horizons. At 25 years the youngest indi-
viduals in the model are aged 40 and becoming eligible 
for NHS Health Checks, so it was not thought suitable to 
project model outcomes beyond this point.
For both analyses, probabilistic sensitivity analysis 
(PSA) was carried out using 2000 model runs to account 
for model non- linearity and to provide an estimate of 
uncertainty around the results.
Patient and public involvement
Patients and the public were not involved in this study.
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RESULTS
Detection of all high risk individuals
Model results indicate that detection of all high risk indi-
viduals followed by current levels of management could 
save £68 billion for the NHS and social care, prevent 
3.4 million CVD events, and gain 4.9 million QALYs over 
the next 25 years compared with current care (table 2 and 
figure 1). The intervention is expected to be cost saving 
(NHS and PSS savings outweigh intervention costs) within 
10 years. Alternatively, if all individuals are also managed 
according to NICE guidelines the health benefits increase 
considerably at all time points, with 5.2 million CVD 
events avoided and 8.1 million QALYs gained by 25 years. 
Cost savings are slightly lower at 25 years (£61 billion) and 
the intervention is not expected to be cost saving until 
year 13; this is due to substantially higher intervention 
costs not entirely offset by greater NHS and PSS savings. 
Distribution of PSA samples on the cost- effectiveness 
plane for the 25 year horizon shows that the vast majority 
of points for both detection scenarios are located in the 
south- eastern quadrant, indicating a high probability of 
being cost saving (supplementary file 2).
Detection of 100% of high risk individuals is projected 
to lead to increases in the cost of all modelled manage-
ment interventions (online supplementary file 2), with 
the highest costs arising due to treatment of previously 
undiagnosed type 2 diabetes and usage of anticoagulants 
in people previously undiagnosed with AF. The model 
also predicts a reduction in costs of NHS Health Check, 
which is due to fewer people meeting eligibility criteria 
because the analysis assumes that the additional detection 
is happening through unspecified opportunistic methods 
and not through the NHS Health Check itself.
Most of the NHS and PSS cost savings come from 
prevention of CVD and microvascular complications 
of diabetes (including ulcer, amputation and retinop-
athy); however, the model predicts small net increases 
(relative to CVD savings) in the costs of end stage renal 
failure, osteoarthritis, breast and bowel cancer, depres-
sion, dementia and major bleed over the lifetime horizon 
Table 1 Summary of deinitions, data and data sources used relating to diagnosis and management of the six CVD high risk 
conditions
CVD high risk conditions Diagnosis Management













10 year QRISK2 score 
≥10% or familial 
hypercholesterolaemia
34%19 No data 
found
11%§9 Lipid modiication therapy; 
antihypertensives; anticoagulants; weight 
management; smoking cessation; blood 
pressure self- monitoring; medicines use 
review
Hypertension BP ≥140/90 or 140/80 
with diabetes or 130/80 
with diabetes and 
chronic kidney disease or 
microvascular disease
28%34 17%36 60% Antihypertensives; weight management; 
smoking cessation; blood pressure self- 
monitoring; medicines use review
Atrial ibrillation Atrial ibrillation 3%35 2.3%36 76% Anticoagulants; weight management; 
smoking cessation; medicines use review
Diabetes Type 1 diabetes 0.6%19 0.6% 100%¶ Lipid modiication therapy; 
antihypertensives; blood glucose lowering 
medication; structured diabetes education; 
weight management; smoking cessation; 
insulin pump; blood pressure self 
monitoring; medicines use review
Type 2 diabetes 7.8%32 6.0%36 78%









Chronic kidney disease 
stage 3a and above
6%33 4%36 65% Antihypertensives; weight management; 
individualised nutritional advice; smoking 
cessation; blood pressure self monitoring; 
medicines use review
*Prevalence in England for individuals aged 16 and over.
†Calculated as diagnosed prevalence/total estimated prevalence.
‡Note that some of these have additional eligibility criteria, for example, only smokers eligible for smoking cessation; only overweight/obese 
eligible for weight management; blood pressure criteria for antihypertensives etc.
§Of patients with a recorded QRISK score. Assumes that recording of QRISK score is independent of value.
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(online supplementary file 2). This is likely to be due to 
several reasons: (1) CVD prevention reduces mortality, 
meaning that people live for longer and so are more likely 
to succumb to other conditions, particularly those with 
a big age component such as cancer, dementia and end 
stage renal failure; (2) being given a diagnosis of diabetes 
is linked to higher rates of depression in the model, so 
increasing detection of diabetes will increase depression 
costs; (3) anticoagulant usage is potentially associated 
with a small increased risk of major bleed, so diagnosing 
more people with AF may result in a higher prevalence of 
major bleed.
Determining who beneits from maximal detection
The results indicate that different high risk groups are 
likely to benefit most from maximising detection in the 
short term (<10 years) compared with the long term 
(>10 years). In the short term, maximising detection 
of individuals with high cholesterol/QRISK2 of at least 
10% accrues the greatest cost savings and QALY gains 
and prevents the most CVD cases (table 3 and figure 2). 
This is likely to occur due to the high population preva-
lence of people with QRISK2 of at least 10%, of which the 
proportion thought to be currently detected is fairly low 
(see table 1), and the high risk of CVD events in the near 
future that these individuals have. At five years, detection 
of most of the high risk groups (with the exception of 
high cholesterol/QRISK2 ≥10% and CKD) is projected to 
cost money overall as insufficient benefits have accrued 
to overcome the initial costs of additional diagnosis and 
management. However, the balance changes over time, 
with cost -savings outweighing intervention costs for the 
diabetes and hypertension subgroups by around 10–15 
years (online supplementary file 2). Note that with the 
exception of diabetes detection at year 25 there is high 
uncertainty around whether or not detection of indi-
vidual conditions will be cost saving (table 3 and online 
supplementary file 2).
In the long term maximising detection of diabetes is the 
most beneficial strategy, which is likely to reflect the long 
term complications associated with the condition and the 
Table 2 Incremental costs, savings and beneits accrued through 100% detection of high risk conditions compared with 
current detection rates. 95% credible intervals obtained through probabilistic sensitivity analysis are shown in brackets













Net total costs £2.4b











































































  of which MI −81 000
(−195 000 to 
−8000)
−189 000
(−429 000 to −36 
000)
−203 000
(−399 000 to 
−53 000)
−402 000








  of which 
stroke
−123 000
(−337 000 to 
−16 000)
−301 000
(−779 000 to 
−63 000)
−299 000











Life years 95 000
(5000 to 233 000)
264 000
(73 000 to 
598 000)
473 000









(45 000 to 
416 000)
540 000
(206 000 to 
1.13m)
747 000
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benefits of early diagnosis. The total benefits that accrue 
to the NHS through maximising detection of AF and 
CKD are relatively small despite the very high risk of CVD 
that these conditions confer due to the low prevalence of 
these conditions in the population (see table 1). Maxi-
mising detection of AF is also the most costly strategy at 
25 years, likely to be due to the relatively high cost of anti-
coagulant treatment compared with most other interven-
tions in the model. Note that the total benefits when all 
high risk groups are detected simultaneously is not iden-
tical to the sum of all benefits when each high risk group 
is detected individually due to some individuals having 
multiple comorbid high risk conditions and so benefiting 
to a greater extent from multiple detection in the former 
analysis, and counted twice in the latter analysis.
For all conditions, management according to NICE 
guidelines produces greater health benefits than 
current management, but also tends to be more costly. 
Interestingly, for diabetes, managing all patients 
according to NICE guidelines is only slightly more 
beneficial than current management (figure 2). This is 
mainly due to the relatively good adherence to NICE 
guidelines for people with diabetes in current prac-
tice, promoted through QOF and the national diabetes 
audit.36 37 PSA indicates that there is a high proba-
bility of cost- effectiveness within 25 years, under both 
Figure 1 Trajectories showing the accumulation of incremental costs, savings and health beneits over the 25 year horizon 
under two scenarios for 100% detection of all high risk conditions: current levels of management (blue) or NICE guideline levels 
of management (orange). CVD, cardiovascular disease; LY, life years; NICE, National Institute for Health and Care Excellence; 
NMB, net monetary beneit; QALY, quality adjusted life year.
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detection scenarios and for all high risk conditions 
(online supplementary file 2).
DISCUSSION
This analysis indicates that large cost savings and health 
benefits could accrue to the NHS if all individuals with 
conditions that increase CVD risk could be detected, with 
detection of undiagnosed diabetes cases likely to produce 
the greatest benefits. Ensuring that all conditions are 
managed according to NICE guidelines once diagnosed 
would further increase the health benefits without 
substantially increasing the costs. Note that most indi-
vidual results are uncertain due to the large number of 
uncertain parameters in the model and the lack of infor-
mation about how these are correlated; however, in most 
cases the balance of probabilities is in favour of additional 
detection and management over the long term. The bene-
fits of detection and management for each high risk condi-
tion vary depending on a number of factors, including 
the proportions currently undiagnosed, the proportions 
currently poorly managed, the costs and effectiveness of 
the key management interventions, and the increased 
risk for CVD and other complications that each condi-
tion confers. In addition to these factors, the high cost 
savings and health benefits estimated over the long term 
for detecting people with diabetes are likely to arise due 
to the particular benefits of early detection of this condi-
tion. Those diagnosed at lower HbA1c levels have a better 
prognosis than those diagnosed at higher HbA1c levels,40 
and so are less likely to progress to expensive treatments 
such as insulin, or develop expensive and seriously detri-
mental complications such as microvascular disease.
The key strength of this analysis is its basis in a single 
modelling framework, which includes most elements of 
current practice in CVD prevention in people at high 
risk, and thereby enables comparison of different detec-
tion and management scenarios. An assessment of some 
of the competing risks for mortality and morbidity is also 
possible due to the inclusion in the model of a range of 
additional conditions, including dementia, depression, 
some cancers and osteoarthritis. Although it is important 
to note that these conditions have been modelled in a less 
sophisticated way than cardiovascular disease, and that 
the model does not include all competing risks, so there 
may be additional long- term costs to preventing CVD not 
included in the model. Furthermore, the patient level 
structure of the model preserves correlations between 
high risk conditions that exist in the English population, 
meaning that the combined benefits of detecting multiple 
high risk conditions can be assessed without double 
counting or underestimating CVD risk in people with 
multiple comorbidities. However, there are also several 
limitations. First, the 100% detection scenario is not a 
realistic target and overestimates the benefits that could 
be reasonably achieved. PHE has produced a set of CVD 
ambitions which include detection of 85% of AF cases, 
80% of hypertension cases, and to have performed a CVD 
risk assessment on 75% of people aged 40–74 by 2029.41 
Setting realistic detection targets for the other high risk 
conditions could help galvanise improvements and would 
Table 3 Net total incremental costs accrued through 100% detection of each high risk condition separately. 95% credible 
intervals obtained through probabilistic sensitivity analysis are shown in brackets







































































































AF, atrial ibrillation; CKD, chronic kidney disease; NDH, non- diabetic hyperglycaemia; NICE, National Institute for Health and Care Excellence.
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allow an estimation of the cost savings and health bene-
fits that could accrue. A second limitation is the ability 
of the model to accurately estimate current care, which 
will impact on the magnitude of the modelled benefits 
and which depends on a range of data sources that vary 
between highly accurate QOF data for diagnosed preva-
lence of most conditions and usage of some interventions 
(eg, anticoagulants),36 published observational studies 
based on a limited sample (eg, the DPP pilot study for 
current uptake of the NHS DPP38) and modelled esti-
mates of total prevalence from NCVIN.32–35 Third, the 
CVD prevention benefits of improving detection and 
management may be underestimated because the model 
only includes the CVD outcomes within QRISK2,29 plus 
congestive heart failure (peripheral vascular disease is 
not included for example), it does not include any CVD 
benefits of lifestyle management interventions that may 
occur above and beyond the recorded effect on metabolic 
factors, and it does not model secondary CVD events in 
a way that enables interventions to directly impact them. 
In addition, the model only includes a limited number 
of conditions unrelated to CVD, and some CVD manage-
ment interventions, particularly lifestyle interventions, 
may have direct benefits that go beyond those included in 
the model. This is particularly true of smoking cessation 
for example, which will have specific benefits in reducing 
lung cancer and chronic obstructive pulmonary disease 
that have not been included in the model.
While this analysis can be used to estimate how much 
money could potentially be spent on interventions to 
improve detection and management in high risk individ-
uals, further research is needed to determine what policy 
changes would be required in practice. There are many 
reasons why people at high risk of CVD are currently insuf-
ficiently diagnosed and managed. Insufficient diagnosis 
may occur partly due to individuals not being offered or 
taking up their NHS Health Check or annual review, or 
not being detected despite their attendance (for example 
NICE guidelines for each condition are inconsistent 
around which other high risk conditions should be tested 
Figure 2 Accrual of health beneits in each high risk group when detection is maximised compared with current care. CVD 
cases prevented (top), life years gained (middle) and QALYs gained (bottom) for 100% detection of each high risk condition 
followed by either current levels of management (left) or NICE guideline levels of management (right). AF, atrial ibrillation; CVD, 
cardiovascular disease; NDH, non- diabetic hyperglycaemia; NICE, National Institute for Health and Care Excellence; QALY, 
quality adjusted life year.
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for during the annual review). Opportunistic mecha-
nisms of detection do exist for some conditions (eg, 
community blood pressure assessments, or using blood 
pressure monitors to detect AF), but even then they are 
not explicitly mentioned in NICE guidelines or consis-
tently available. Poor management may be due to clin-
ical practice not always following NICE guidelines, but 
may also be owing to patients choosing not to undergo 
treatment, poorly adhering to treatment or discontinuing 
treatment. Each of these issues would require different 
strategies for improvement, from changing guidelines 
to ensure detection of all six conditions is maximised at 
NHS Health Check and annual review; to incentivising 
best practice, perhaps through developing new QOF indi-
cators; to developing strategies to improve opportunistic 
detection of high risk conditions, and patient uptake and 
adherence to interventions. A further barrier to improve-
ment is the short- term nature of much decision making, 
when improvements to health and cost savings will not 
be realised until far into the future. Further research is 
required to identify the reasons for insufficient detection 
and management of high risk conditions and to develop 
acceptable and cost- effective solutions.
In summary, this analysis has shown that improving 
detection and management of the six CVD high risk 
groups identified through the NHS RightCare pathway 
is likely to result in significant health benefits and cost 
savings. There are other population groups at particularly 
high risk of CVD, including people with obesity, those 
with learning difficulties and those with mental illness. 
Further health benefits and cost savings could potentially 
be obtained through improving CVD risk management 
of these individuals. Primary prevention of CVD in the 
general population, including preventing high risk condi-
tions from developing in the first place, is also likely to 
be highly cost effective, and could be evaluated as part of 
future work within the same modelling framework.
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